Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

Malignant Glioma Clinical Trial

— ACTION  

Official title:

ACTION: A Longitudinal Observational Study of Quality of Life, Functional Capacity and Physical Function in Glioblastoma Patients Treated With Tumor-Treating Fields

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03501134
• Other study ID #: Pro00088890
• Status: Completed
• Start date: August 8, 2018
• Est. completion date: June 3, 2021

Study information

• Verified date: June 2021
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).

Description:

Patients will be provided with a Fitbit Charge HR™, which they will begin wearing immediately to collect baseline information. The study team will teach the patients how to use the Fitbit and the associated smart phone application. Patients will also set an account with a platform that will provide information from the Fitbit (number of steps, sleep behaviors, and exercise log) to the study team. Patients will also have blood drawn, do a 6-minute walk test, and complete questionnaires at clinic visits 1, 8, 16, and 24 weeks after receiving the Fitbit. At the end of the study, patients will return the Fitbit to the study team.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 3, 2021
• Est. primary completion date: June 3, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent prior to beginning specific protocol procedures
• Histologically proven World Health Organization (WHO) grade IV malignant glioma
• Completed standard-of-care treatment for newly diagnosed WHO grade IV malignant glioma, consisting of temozolomide (TMZ) and radiation therapy (RT)
• Signed Optune™ Prescription Form indicating intention of initiating NovoTTF therapy
• Stable disease status
• Patients = 18 years of age
• Karnofsky Performance Status (KPS) = 70
• Patient must be able to ambulate and complete the 6-minute walk test without use of a walker, cane, or any assist device
• Technology requirement:
• Patients need to own a smart phone that can interface with the Fitbit Charge HR™.
• Patients must be willing to provide their own internet access for this study. This will include either a data plan or Wi-Fi access on the patient's smart phone for use of the Fitbit Charge HR™ App. They will also need internet access (through their smart phone or home computer) for setting up a SGHIx account. Patients are welcome to use the free guest Wi-Fi access within the Duke Outpatient clinic area for the purpose of this study.
• Patients will need a home computer or adaptor with USB port to charge the Fitbit Charge HR™.

Exclusion Criteria:

• Non-English speaking or inability to read and understand English.
• Presence of cardiovascular disease that would make physical activity risky, at the discretion of the provider.
• Any patient who is unable to comprehend and operate the activity tracker, at the discretion of the enrolling provider.

Related Conditions & MeSH terms

• Glioblastoma
• Glioma
• Malignant Glioma

Intervention

Device:
• NovoTTF
We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.

Locations

Country	Name	City	State
United States	The Preston Robert Tisch Brain Tumor Center at Duke	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	NovoCure Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in physical activity between baseline and week 24	Mean change between baseline and week 24 in total physical activity (MET-h/wk) as measured by the Godin Leisure Time Questionnaire	Baseline, 24 weeks
Secondary	Change in quality of life between baseline and week 24	Mean change from baseline at week 24 in subscales of the Functional Assessment of Cancer Therapy Brain (FACT-Br) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F)	Baseline, 24 weeks
Secondary	Change in sleep quality between baseline and week 24	Mean change from baseline at week 24 in sleep quality as measured by the Pittsburgh Sleep Quality Assessment (PSQI)	Baseline, 24 weeks
Secondary	Change in patient's mood state between baseline and week 24	Mean change from baseline at week 24 in mood as measured by the Beck Depression Inventory (BDI)	Baseline, 24 weeks
Secondary	Change in functional capacity between baseline and week 24	Mean change from baseline at week 24 in functional capacity as measured by the 6-minute walk test	Baseline, 24 weeks
Secondary	Change from baseline in average daily number of steps taken at 8, 16, and 24 (±3) weeks	Mean change from baseline at week 8, 16, and 24 in the average daily number of steps as measured by the Fitbit among patients treated with Novo TTF	Baseline, 8, 16, 24 weeks

External Links

•   Duke Cancer Institute
•   The Preston Robert Tisch Brain Tumor Center at Duke